Therapeutics
In this section you will find Therapeutics market research reports and publications. These provide information on the latest products, news, market growth forecasts, data and business opportunities of value to your organization.
-
Analytical Tool - Leukemia
$4,295.00Published by BioSeeker Group on Apr 22nd, 2013A unique tool for analyzing the complex competitive pressure within the different fields of leukemia therapeutics. Learn More -
IL-2 Signaling Pathway in Oncology Drug Pipeline Update 2013
$2,050.00Published by BioSeeker Group on Apr 22nd, 2013BioSeeker Group have identified 229 companies plus partners who are today developing 329 IL-2 pathway targeting drugs in 1082 developmental projects in cancer across 142 different targets. In addition, there are 6 suspended drugs and another 117 drugs where development has been ceased. Learn More -
Angiogenesis in Oncology Drug Pipeline Update 2013
$2,050.00Published by BioSeeker Group on Apr 22nd, 2013BioSeeker Group have identified 256 companies plus partners who are today developing 263 angiogenesis drugs in 1107 developmental projects in cancer across 202 different targets. In addition, there are 6 suspended drugs and another 142 drugs where development has been ceased. Learn More -
Analytical Tool - Antibodies and Peptides in Oncology
$7,950.00Published by BioSeeker Group on Apr 22nd, 2013A unique tool for analyzing the vast amount of strategic possibilities that have emerged in antibody and peptide cancer R&D and business development. Learn More -
T Cell Receptor Signaling Pathway in Oncology Drug Pipeline Update 2013
$2,050.00Published by BioSeeker Group on Apr 22nd, 2013BioSeeker Group have identified 219 companies plus partners who are today developing 270 T cell receptor pathway targeting drugs in 972 developmental projects in cancer across 169 different targets. In addition, there are 7 suspended drugs and another 144 drugs where development has been ceased. Learn More -
Brain Cancer Drug Pipeline Update 2013
$2,050.00Published by BioSeeker Group on Apr 22nd, 2013BioSeeker Group have identified 201 companies plus partners who are today developing 181 drugs targeting brain cancer in development. across 168 different targets. In addition, there are 3 suspended drugs and another 73 drugs where development has been ceased. Learn More -
Analytical Tool - Hematological Cancers
$7,950.00Published by BioSeeker Group on Apr 22nd, 2013"Analytical Tool Hematological Cancers" offers a unique tool for analyzing the vast amount of strategic possibilities that have emerged in R&D and business development in hematological cancers. Learn More -
Proteins in Oncology Drug Pipeline Update 2013
$2,050.00Published by BioSeeker Group on Apr 22nd, 2013BioSeeker Group have identified 308 companies plus partners who are today developing 334 protein drugs in 583 developmental projects in cancer across 163 different targets. In addition, there are 2 suspended drugs and another 168 drugs where development has been ceased. Learn More -
Kit Receptor Signaling Pathway in Oncology Drug Pipeline Update 2013
$2,050.00Published by BioSeeker Group on Apr 22nd, 2013BioSeeker Group have identified 160 companies plus partners who are today developing 248 Kit receptor pathway targeting drugs in 970 developmental projects in cancer across 131 different targets. In addition, there are 2 suspended drugs and another 101 drugs where development has been ceased. Learn More -
Analytical Tool - Protein Kinase Inhibitors in Oncology
$5,895.00Published by BioSeeker Group on Apr 22nd, 2013Adopt knowledge from this analysis to drive strategic planning decisions in PKI drug development in oncology. Learn More -
Analytical Tool - Peptides in Oncology
$4,295.00Published by BioSeeker Group on Apr 22nd, 2013A unique tool for analyzing the vast amount of strategic possibilities that have emerged in cancer peptide R&D and business development. Learn More -
Analytical Tool - Cancer Vaccines
$4,295.00Published by BioSeeker Group on Apr 22nd, 2013The ultimate tool for serious players who would like to understand the current competitive field in cancer vaccine development. Learn More -
Wnt Signaling Pathway in Oncology Drug Pipeline Update 2013
$1,499.00Published by BioSeeker Group on Apr 22nd, 2013BioSeeker Group have identified 103 companies plus partners who are today developing 109 Wnt pathway targeting drugs in 385 developmental projects in cancer across 129 different targets. In addition, there is 1 suspended drug and another 46 drugs where development has been ceased. Learn More -
Analytical Tool - Breast Cancer
$4,295.00Published by BioSeeker Group on Apr 22nd, 2013The ultimate tool for serious players who would like to understand the current competitive field in breast cancer drug development. Learn More -
Pancreatic Cancer Drug Pipeline Update 2013
$2,050.00Published by BioSeeker Group on Apr 22nd, 2013BioSeeker Group have identified 249 companies plus partners who are today developing 290 drugs targeting pancreatic cancer in development. across 235 different targets. In addition, there are 3 suspended drugs and another 101 drugs where development has been ceased. Learn More
Therapeutics
In this section you will find Therapeutics market research reports and publications. These provide information on the latest products, news, market growth forecasts, data and business opportunities of value to your organization.
-
Analytical Tool - Leukemia
$4,295.00Published by BioSeeker Group on Apr 22nd, 2013A unique tool for analyzing the complex competitive pressure within the different fields of leukemia therapeutics. Learn More -
IL-2 Signaling Pathway in Oncology Drug Pipeline Update 2013
$2,050.00Published by BioSeeker Group on Apr 22nd, 2013BioSeeker Group have identified 229 companies plus partners who are today developing 329 IL-2 pathway targeting drugs in 1082 developmental projects in cancer across 142 different targets. In addition, there are 6 suspended drugs and another 117 drugs where development has been ceased. Learn More -
Angiogenesis in Oncology Drug Pipeline Update 2013
$2,050.00Published by BioSeeker Group on Apr 22nd, 2013BioSeeker Group have identified 256 companies plus partners who are today developing 263 angiogenesis drugs in 1107 developmental projects in cancer across 202 different targets. In addition, there are 6 suspended drugs and another 142 drugs where development has been ceased. Learn More -
Analytical Tool - Antibodies and Peptides in Oncology
$7,950.00Published by BioSeeker Group on Apr 22nd, 2013A unique tool for analyzing the vast amount of strategic possibilities that have emerged in antibody and peptide cancer R&D and business development. Learn More -
T Cell Receptor Signaling Pathway in Oncology Drug Pipeline Update 2013
$2,050.00Published by BioSeeker Group on Apr 22nd, 2013BioSeeker Group have identified 219 companies plus partners who are today developing 270 T cell receptor pathway targeting drugs in 972 developmental projects in cancer across 169 different targets. In addition, there are 7 suspended drugs and another 144 drugs where development has been ceased. Learn More -
Brain Cancer Drug Pipeline Update 2013
$2,050.00Published by BioSeeker Group on Apr 22nd, 2013BioSeeker Group have identified 201 companies plus partners who are today developing 181 drugs targeting brain cancer in development. across 168 different targets. In addition, there are 3 suspended drugs and another 73 drugs where development has been ceased. Learn More -
Analytical Tool - Hematological Cancers
$7,950.00Published by BioSeeker Group on Apr 22nd, 2013"Analytical Tool Hematological Cancers" offers a unique tool for analyzing the vast amount of strategic possibilities that have emerged in R&D and business development in hematological cancers. Learn More -
Proteins in Oncology Drug Pipeline Update 2013
$2,050.00Published by BioSeeker Group on Apr 22nd, 2013BioSeeker Group have identified 308 companies plus partners who are today developing 334 protein drugs in 583 developmental projects in cancer across 163 different targets. In addition, there are 2 suspended drugs and another 168 drugs where development has been ceased. Learn More -
Kit Receptor Signaling Pathway in Oncology Drug Pipeline Update 2013
$2,050.00Published by BioSeeker Group on Apr 22nd, 2013BioSeeker Group have identified 160 companies plus partners who are today developing 248 Kit receptor pathway targeting drugs in 970 developmental projects in cancer across 131 different targets. In addition, there are 2 suspended drugs and another 101 drugs where development has been ceased. Learn More -
Analytical Tool - Protein Kinase Inhibitors in Oncology
$5,895.00Published by BioSeeker Group on Apr 22nd, 2013Adopt knowledge from this analysis to drive strategic planning decisions in PKI drug development in oncology. Learn More -
Analytical Tool - Peptides in Oncology
$4,295.00Published by BioSeeker Group on Apr 22nd, 2013A unique tool for analyzing the vast amount of strategic possibilities that have emerged in cancer peptide R&D and business development. Learn More -
Analytical Tool - Cancer Vaccines
$4,295.00Published by BioSeeker Group on Apr 22nd, 2013The ultimate tool for serious players who would like to understand the current competitive field in cancer vaccine development. Learn More -
Wnt Signaling Pathway in Oncology Drug Pipeline Update 2013
$1,499.00Published by BioSeeker Group on Apr 22nd, 2013BioSeeker Group have identified 103 companies plus partners who are today developing 109 Wnt pathway targeting drugs in 385 developmental projects in cancer across 129 different targets. In addition, there is 1 suspended drug and another 46 drugs where development has been ceased. Learn More -
Analytical Tool - Breast Cancer
$4,295.00Published by BioSeeker Group on Apr 22nd, 2013The ultimate tool for serious players who would like to understand the current competitive field in breast cancer drug development. Learn More -
Pancreatic Cancer Drug Pipeline Update 2013
$2,050.00Published by BioSeeker Group on Apr 22nd, 2013BioSeeker Group have identified 249 companies plus partners who are today developing 290 drugs targeting pancreatic cancer in development. across 235 different targets. In addition, there are 3 suspended drugs and another 101 drugs where development has been ceased. Learn More